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Abstract
Background: Smoking and metabolic syndrome are known to be related to cardiovascular diseases (CVD) risk. In Asian 
countries, prevalence of obesity has increased and smoking rate in men is still high. We investigated the attribution of 
the combination of smoking and metabolic syndrome (or obesity) to excess CVD deaths in Japan.
Methods: A cohort of nationwide representative Japanese samples, a total of 6650 men and women aged 30-70 at 
baseline without history of CVD was followed for 15 years. Multivariate-adjusted hazard ratio for CVD death according 
to the combination of smoking status and metabolic syndrome (or obesity) was calculated using Cox proportional 
hazard model. Population attributable fraction (PAF) of CVD deaths was calculated using the hazard ratios.
Results: During the follow-up period, 87 men and 61 women died due to CVD. The PAF component of CVD deaths in 
non-obese smokers was 36.8% in men and 11.3% in women, which were higher than those in obese smokers (9.1% in 
men and 5.2% in women). The PAF component of CVD deaths in smokers without metabolic syndrome was 40.9% in 
men and 11.9% in women, which were also higher than those in smokers with metabolic syndrome (7.1% in men and 
3.9% in women).
Conclusion: Our results indicated that a large proportion of excess CVD deaths was observed in smokers without 
metabolic syndrome or obesity, especially in men. These findings suggest that intervention targeting on smokers, 
irrespective of the presence of metabolic syndrome, is still important for the prevention of CVD in Asian countries.
Background
Obesity and clustering of its related factors, now called as
metabolic syndrome, have been widely reported as
important risk factors for cardiovascular diseases (CVD)
[1-6], and, also in Asian countries including Japan, obe-
sity has emerged as a new health problem [5]. The
National Health and Nutrition Survey in Japan in 2005
showed that 22.4% of adult men and 10.8% of adult
women were diagnosed as having metabolic syndrome
[7]. Therefore, it is expected that metabolic syndrome or
obesity would contribute to a large part of excess CVD
events in Japan.
On the other hand, cigarette smoking is an established
risk factor for CVD [8-12] and one of the biggest health
problems in Asian countries including Japan [9,12,13]. In
Asian countries, smoking rate in men is still high at 40 to
50% [14]. In Japan, smoking rate in 2005 was also high at
39.3% in men [15]. Therefore, smoking has largely con-
tributed to increase CVD events in Asia, and it was
r e p o r t e d  t h a t  u p  t o  3 0 %  o f  c a r d i o v a s c u l a r  d e a t h s  w a s
attributed by smoking in Asia Pacific region [16].
However, there have been few reports on the attribu-
tion of the combination of smoking status and metabolic
syndrome (or obesity) to CVD deaths in Asian countries.
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Several previous studies also reported that CVD risk was
high in both smokers and non-smokers with clustering of
metabolic risk factors [17]. Therefore, it is important to
elucidate the attribution of obesity, metabolic syndrome,
and smoking to CVD mortality in Asia, where obesity is
still less common compared with Western countries.
The purpose of this report is to examine excess CVD
deaths and population attributable fractions on CVD
deaths by the combination of smoking and metabolic syn-
drome (or obesity) in a 15-year cohort study of randomly
selected representative Japanese samples from the
National Survey on Circulatory Disorders of Japan.
Methods
Participants and follow-up
Cohort studies of the National Survey on Circulatory Dis-
orders of Japan comprise the National Integrated Project
for Prospective Observation of Non-communicable Dis-
ease and Its Trends in the Aged (NIPPON DATA). Base-
line surveys for the cohort of this report were performed
in 1990 (NIPPON DATA90) [18,19]. We analyzed the 15-
year follow-up data of NIPPON DATA90 in this report.
A total of 8383 men and women aged ≥ 30 years from
300 randomly selected districts were participated in the
survey in 1990. The baseline surveys were carried out at
local public health centers. The participation rate in the
baseline survey was 76.5%. The present study was for
7329 participants aged 30 to 70 years at baseline. From
these participants, we excluded 379 participants who had
a history of coronary heart disease or stroke (n = 249) or
who had missing information in the baseline survey (n =
130). Thus, 6650 participants (2752 men and 3898
women) were eligible for the analyses.
NIPPON DATA90 has completed follow-up surveys
until 2005. We used the National Vital Statistics data to
indentify the cause of death. The underlying causes of
death in the National Vital Statistics were coded accord-
ing to the 9th International Classification of Disease (ICD-
9) until the end of 1994 and according to the 10th Interna-
tional Classification of Disease (ICD-10) from 1995.
Deaths from any CVD were identified by ICD-9 codes
(393-459) and ICD-10 codes (I00-I99). The details of the
classification are described elsewhere [18,19]. The Insti-
tutional Review Board of Shiga University of Medical Sci-
ence (NO.12-18, 2000) approved the study.
Biochemical and physical examinations
Public health nurses obtained data including smoking
habit, as well as current health status and medical history.
Public health nurses asked all participants about current
smoking status (current smoking, past smoking and
never-smoking), the number of cigarettes per day and the
duration of smoking. Smoking habit was categorized into
non-smoker, past smoker and current smoker. Drinking
habit was categorized into non-drinker, past drinker,
occasional drinker and daily drinker. Body mass index
was calculated as weight divided by height squared (kg/
m2).
Non-fasting blood samples were obtained at the base-
line survey. The serum was separated and centrifuged
soon after blood coagulation. Plasma samples were col-
lected in siliconized tubes containing sodium fluoride
and shipped to one laboratory (SRL, Tokyo, Japan) for
blood measurements. Plasma glucose was measured
enzymatically. Serum triglycerides and total cholesterol
were also measured enzymatically, and high density lipo-
protein (HDL) cholesterol was measured after heparin-
calcium precipitation [20].
We defined metabolic risk factors using the Japanese
criteria of the metabolic syndrome [21,22] as follow: obe-
sity as body mass index ≥ 25 kg/m2; high blood pressure:
BP ≥ 130/85 mm Hg or on treatment for hypertension;
high blood glucose: serum glucose ≥ 110 mg/dl or on
treatment for diabetes; dyslipidemia: serum triglyceride ≥
150 mg/dl, HDL cholesterol < 40 mg/dl or on treatment
for dyslipidemia. We defined the metabolic syndrome as
having obesity (defined as body mass index ≥ 25 kg/m2)
and two or more other metabolic risk factors; the defini-
tion was modified from the Japanese criteria [22] where
the presence of obesity is essential. We defined metabolic
risk factors clustering as having two or more metabolic
risk factors.
Statistical analysis
Multivariate-adjusted hazard ratios (HR) of all CVD
deaths for each component of metabolic risk factors
including BMI, systolic BP (SBP), triglyceride, glucose,
HDL cholesterol were calculated using Cox proportional
hazards models. Multivariate-adjusted HR for all CVD
deaths according to metabolic risk factors and smoking
categories were calculated using Cox proportional haz-
ards models adjusted for age and drinking. Non-smokers
without metabolic syndrome or obesity were set as the
reference group.
Population attributable fractions (PAF) for CVD deaths
due to the combination of smoking and metabolic syn-
drome (or obesity) were calculated based on hazard ratios
assessed by proportional hazards models [23,24]. PAF
was estimated as pd × (HR-1)/HR where pd is the propor-
tion of death cases arising from the each categories. All
analyses were performed by SAS 9.1 (Statistical Analysis
System, Cary, NC).
Results
Baseline characteristics are shown in Table 1. Mean age at
baseline was 49.9 years in men and 49.0 years in women.
Mean body mass index was 23.1 kg/m2 in men and 22.9
kg/m2 in women. Smoking rate was 58.0% in men andTakashima et al. BMC Public Health 2010, 10:306
http://www.biomedcentral.com/1471-2458/10/306
Page 3 of 9
9.6% in women. The prevalence of hypertension and obe-
sity were 66.9% and 25.1% in men and 54.4% and 23.4% in
women.
During 15 years of follow-up, 87 men and 61 women
died due to CVD (37 men and 22 women died due to
stroke and 30 men and 8 women died due to coronary
heart disease). Table 2 shows HRs of CVD death for each
component of metabolic risk factors including all factors
in a model, simultaneously. It showed that current smok-
ing, past-smoking, SBP and glucose were significant risk
factors of CVD mortality. Table 3 shows adjusted HRs
and PAFs for CVD deaths according to the combination
of obesity and smoking status. Irrespective of obesity,
smoking and CVD mortality in both men and women
were positively related. HRs (95% confidence interval
[CI]) for non-obese smokers was 3.13 (1.33 to 7.36) in
men and 4.32 (1.99 to 9.37) in women compared with
non-obese, non-smokers. Estimated numbers of excess
CVD deaths (and PAF component) in the non-obese
smokers and obese smokers were 32.0 (36.8%), and 7.9
(9.1%) in men and 6.9 (11.3%) and 3.2 (5.2%) in women.
The sum of the estimated number of excess CVD deaths
(PAF) due to smoking and/or obesity was 49.3 (56.9%) in
men and 15.3 (25.1%) in women.
Table 4 shows adjusted HRs and PAF components due
to combination of smoking status and metabolic syn-
drome. Compared to non-smokers without metabolic
syndrome, adjusted HRs (95% CI) for CVD deaths was
higher in smokers with and without metabolic syndrome
(HR 3.19 [1.13 to 9.03] and 3.47 [1.48 to 8.12] in men; 4.94
[1.52 to 16.09] and 3.63 [1.75 to 7.50] in women, respec-
tively). PAFs for CVD mortality in smokers with and
without metabolic syndrome were 7.1% and 40.9% in men
and 3.9% and 11.9% in women, respectively. The sum of
PAF components due to smoking and/or metabolic syn-
drome was 60.4% in men and 17.0% in women.
Table 5 shows adjusted HRs and PAF components due
to the combination of smoking status and clustering of
metabolic risk factors. Compared to non-smokers with-
out metabolic risk factor clustering, adjusted HRs (95%
CI) for CVD death in smokers with and without meta-
bolic risk factor clustering were 5.85 (1.40 to 24.38) and
4.17 (0.98 to 17.71) for men, and 5.86 (2.41 to 14.23) and
4.56 (1.62 to 12.87) for women, respectively. PAF compo-
nents for CVD mortality in non-smokers with metabolic
risk factors clustering, smokers without metabolic risk
factors clustering and smokers with metabolic risk factors
clustering were 2.8%, 20.1% and 34.3% for men, and
18.7%, 6.4% and 10.9% for women, respectively.
Table 2: Adjusted HR for 1 standard deviation increasing in the 
continuous variables and sex, smoking and drinking habits for 
mortality from cardiovascular diseases.
Adjusted hazard 
ration (95%CI)
Current -smoker 3.45 (2.12 -5.60)
Past-smoker 2.04 (1.11 -3.75)
Body mass index (1 SD increasing) 0.99 (0.83 -1.18)
Systolic blood pressure (1 SD increasing) 1.32 (1.13 -1.54)
Triglyceride (1 SD increasing)* 0.85 (0.69 -1.04)
High density lipoprotein cholesterol (1 SD 
increasing)
0.93 (0.76 -1.11)
Glucose (1 SD increasing) 1.10 (1.00 -1.24)
Female 1.00 (0.61 -1.64)
This Cox model also includes age, and drinking habit.
* The variable was tested after log-transferred.
Table 1: Baseline characteristics of study population. NIPPON 
DATA90, men and women aged 30 to 70 years in 1990.
Men Women
Number (N) 2752 3898
Age (year) 49.9 ±11.2 49.0 ±11.3
BMI (kg/m2) 23.1 ±3.0 22.9 ±3.3
SBP (mmHg) 136.2 ±19.5 131.3 ±19.9
DBP (mmHg) 83.8 ±11.7 79.4 ±11.8
Total cholesterol (mg/dl) 199.6 ±36.6 205.5 ±38.0
HDL cholesterol (mg/dl) 50.4 ±15.0 57.5 ±14.9
Triglyceride (mg/dl) 151.8 ±108.8 119.1 ±79.8
Blood glucose (mg/dl) 102.0 ±33.4 101.1 ±28.9
Drinking
Non drinker 921 33.5% 3572 91.6%
Ex-drinker 141 5.1% 39 1.0%
Current drinker 1690 61.4% 287 7.4%
Smoking
Never smoker 556 20.2% 3431 88.0%
Ex-smoker 601 21.8% 94 2.4%
Current smoker 1595 58.0% 373 9.6%
Obesity 689 25.1% 912 23.4%
High blood pressure 1840 66.9% 2119 54.4%
High blood glucose 578 21.0% 829 21.3%
Dyslipidemia 1280 46.5% 1094 28.1%
Values are number, %, or mean ± SD.
High blood pressure, BP ≥ 130/85 mmHg or on treatment of 
hypertension; high blood glucose, blood glucose≥ 110 mg/dl or on 
treatment of diabetes; dyslipidemia as triglyceride≥ 150 mg/dl or 
high density lipoprotein < 40 mg/dl or on treatment of dyslipidemia.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HDL, high density lipoprotein.T
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Table 3: Hazard ratio and population attributable fraction for cardiovascular disease deaths according to the combination of smoking status and obesity*: NIPPON DATA90
Number of 
participants
Person-years of 
follow-up
CVD 
deaths (n)
CVD mortality rate 
(per 1,000 person-
years)
Adjusted hazard ratio (95% CI)† Estimated excess 
CVD deaths (n)
PAF component for 
CVD deaths (%)
Men
Non smoker Non-obese 420 5938 6 1.01 1.00
Obese 136 1988 1 0.50 0.67 (0.08 -5.53) -- --
Past smoker Non-obese 431 6116 16 2.62 1.93 (0.75 -4.96) 7.7 8.8
Obese 170 2414 5 2.07 1.52 (0.46 -4.99) 1.7 2.0
Smoker Non-obese 1212 16780 47 2.80 3.13 (1.33 -7.36) 32.0 36.8
Obese 383 5277 12 2.27 2.92 (1.09 -7.82) 7.9 9.1
Women
Non smoker Non-obese 2,638 37960 29 0.76 1.00
Obese 793 11256 17 1.51 1.34 (0.74 -2.45) 4.3 7.1
Past smoker Non-obese 66 843 1 1.19 1.43 (0.19 -10.61) 0.3 0.5
Obese 28 383 1 2.61 2.46 (0.33 -18.09) 0.6 1.0
Smoker Non-obese 282 3889 9 2.31 4.32 (1.99 -9.37) 6.9 11.3
Obese 91 1224 4 3.27 4.74 (1.66 -13.58) 3.2 5.2
*Obesity was defined as body mass index ≥ 25 kg/m2.
†Hazard ratios were adjusted for age and drinking.
CVD, cardiovascular diseases; PAF, population attributable fraction; CI, confidence interval.T
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Table 4: Hazard ratio and population attributable fraction for cardiovascular disease deaths according to the combination of smoking status and metabolic 
syndrome: NIPPON DATA90.
Metabolic 
syndrome*
Number of 
participants
Person-years of 
follow-up
CVD deaths (n) CVD mortality 
rate (per 1,000 
person-years)
Adjusted hazard ratio( 95% CI) † Estimated excess 
CVD deaths (n)
PAF component for 
CVD deaths (%)
Men
Non smoker - 480 6817 6 0.88 1.00
+ 76 1109 1 0.90 1.32 (0.16 -10.97) 0.2 0.3
Past smoker - 494 7036 18 2.56 2.13 (0.84 - 5.39) 9.5 11.0
+ 107 1494 3 2.01 1.49 (0.37 - 6.01) 1.0 1.1
Smoker - 1343 18620 50 2.69 3.47 (1.48 - 8.12) 35.6 40.9
+ 252 3437 9 2.62 3.19 (1.13 - 9.03) 6.2 7.1
Women
Non smoker - 3,034 43585 38 0.87 1.00
+ 397 5631 8 1.42 0.83 (0.38 - 1.78) -- --
Past smoker - 81 1042 1 0.96 1.06 (0.15 - 7.81) 0.05 0.1
+ 13 184 1 5.45 2.98 (0.41 -21.79) 0.6 1.1
Smoker - 336 4627 10 2.16 3.63 (1.75 - 7.50) 7.2 11.9
+ 37 486 3 6.17 4.94 (1.52 -16.09) 2.4 3.9
*Metabolic syndrome were defined as follows: obesity (body mass index ≥ 25 kg/m2) plus any two of the following three factors: high blood pressure as blood pressure ≥ 130/85 mmHg or on 
treatment of hypertension, high blood glucose as blood glucose ≥ 110 mg/dl or on treatment of diabetes, dyslipidemia as triglyceride ≥ 150 mg/dl or high density lipoprotein cholesterol <40 mg/
dl or on treatment of dyslipidemia.
†Hazard ratios were adjusted for age and drinking.
CVD, cardiovascular diseases; PAF, population attributable fraction; CI, confidence interval.T
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Table 5: Hazard ratio and population attributable fraction for cardiovascular disease deaths according to the combination of smoking status and clustering of 
metabolic risk factors: NIPPON DATA90.
Clustering of 
metabolic risk 
factors*
Number of 
participants
Person-years of 
follow-up
CVD 
deaths (n)
CVD mortality 
rate (per 1,000 
person-years)
Adjusted hazard ratio (95% CI) † Estimated 
excess CVD 
deaths (n)
PAF component for 
CVD deaths (%)
Men
Non smoker 0 or 1 281 4002 2 0.50 1.00
2 ≤ 275 3924 5 1.27 1.94 (0.38 -10.00) 2.4 2.8
Past smoker 0 or 1 282 4084 7 1.71 2.41 (0.50 -11.65) 4.1 4.7
2 ≤ 319 4446 14 3.15 3.37 (0.76 -14.96) 9.8 11.3
Smoker 0 or 1 819 11465 23 2.01 4.17 (0.98 -17.71) 17.5 20.1
2 ≤ 776 10592 36 3.40 5.85 (1.40 -24.38) 29.8 34.3
Women
Non smoker 0 or 1 2,117 30554 14 0.46 1.00
2 ≤ 1314 18661 32 1.71 1.55 (0.82 -2.95) 11.4 18.7
Past smoker 0 or 1 54 698 0 -- -- -- --
2 ≤ 40 527 2 3.79 3.08 (0.69 -13.81) 1.4 2.2
Smoker 0 or 1 222 3098 5 1.61 4.56 (1.62 -12.87) 3.9 6.4
2 ≤ 151 2016 8 3.97 5.86 (2.41 -14.23) 6.6 10.9
*Metabolic risk factors were any of the following four factors: obesity (body mass index ≥ 25 kg/m2), high blood pressure as blood pressure ≥ 130/85 mmHg or on treatment of hypertension, high 
blood glucose as blood glucose ≥ 110 mg/dl or on treatment of diabetes, dyslipidemia as triglyceride ≥ 150 mg/dl or high density lipoprotein cholesterol < 40 mg/dl or on treatment of dyslipidemia.
†Hazard ratios were adjusted for age and drinking.
CVD, cardiovascular diseases; PAF, population attributable fraction; CI, confidence interval.Takashima et al. BMC Public Health 2010, 10:306
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Discussion
The present report of a representative Japanese cohort
showed that the majority of excess CVD deaths were
observed in smokers without metabolic syndrome. The
PAF component of CVD deaths in smokers without met-
abolic syndrome were 5 times higher than those in partic-
ipants with metabolic syndrome in men (40.9% vs. 8.5%).
The HR of CVD deaths in smokers without metabolic
syndrome were also higher than non-smokers without
metabolic syndrome, and it was similar to the HR in
smokers with metabolic syndrome (3.47 vs. 3.19).
In Asian countries including Japan, there has been a
rise in metabolic syndrome [7,25]. In these areas, preva-
lence of smoking has been higher than that in Western
countries and smoking rates has been still increasing in
younger women [14]. Previous studies have reported that
obesity and smoking are risk factors for CVD [5,6,10,11].
The association of clustering of metabolic risk factors,
including hyperglycemia, dyslipidemia, and hyperten-
sion, with CVD risk has also been widely reported
[1,4,17,18]. Furthermore, a previous study from Japan
reported that the effect of risk factor accumulation on
CVD incidence was more evident among smokers than
non smokers [17]. However, these previous reports did
not show the attribution of the combination of smoking
and metabolic syndrome (or obesity) to CVD events. To
our knowledge, this is the first report showing that the
majority of excess CVD deaths occurred in smokers with-
out metabolic syndrome in a Asian population. A
strength of our report is that the study was conducted in a
15-year cohort of nationwide representative Japanese
samples.
In Japan, new health checkups and healthcare advice
focusing on the metabolic syndrome to prevent CVD
began in April 2008 through health insurance providers
[7]. Our results support the necessity of intervention for
people with metabolic syndrome because these people
appear to be at higher CVD risk; however, PAF compo-
nent in men and in women with metabolic syndrome
were only 8.5% and 5.0%, respectively. On the other hand,
the present study indicated that PAFs among smokers
without metabolic syndrome were 40.9% in men and
11.9% in women; who are not the target population of the
new health educational program in Japan. Moreover, not
only PAF but also HR of smokers without metabolic syn-
drome was substantially higher. Thus the program might
overlook a large population at an increased risk of CVD.
Activities of smoking cessation for non-obese people
would be still important for the prevention of CVD in
Japan.
In the present study, we examined the association
between each component of metabolic risk factors and
CVD death. We conformed that current and past smok-
ing, SBP and glucose were significant risk factors of CVD
mortality in our study participants. Several previous
reports revealed that clustering of metabolic risk factors
increases CVD risk, irrespective of the presence of obe-
sity [17,18]. When obesity was dealt with one of meta-
bolic risk factors (not an essential factor) in the present
study (Table 5), the PAF in smokers with metabolic risk
factor clustering got larger in men (34.3%). However,
even for smokers without metabolic risk factors cluster-
ing in the present study, PAF was 20.1% in men. This
finding indicated that even if obesity is not essential for
the diagnostic criteria of metabolic syndrome like the
National Cholesterol Education Program (NCEP) [26], an
intervention for smokers without clustering of metabolic
risk factors would be also important for the prevention of
CVD.
This study has several limitations. First, we used non-
fasting blood samples and thus we might have misclassi-
fied several individuals with diabetes and dyslipidemia.
Second, we used body mass index ≥ 25 kg/m2 to define
obesity and thus we might have misclassified individuals
with abdominal obesity with higher waist circumference.
However, this limitation would be ignorable because the
correlation between BMI and waist circumstance is usu-
ally high enough. The cut-off point of body mass index
for Japanese [21] is different from that for Asia-Pacific
Region in the WHO definition (body mass index ≥ 23 kg/
m2) [27], which may underestimate the PAF in Asian peo-
ple. Third, we did not adjust for socioeconomic status in
this study. However, all Japanese are covered by the
national health insurance program and socioeconomic
status would not limit access to treatment in Japan.
Fourth, in this study, we used information on smoking
habit from self-reported smoking history; this may cause
recall and information biases. Fifth, the numbers of par-
ticipants or CVD events were not enough to analyze
according to the number of cigarettes per day; therefore,
we did not consider the intensity of smoking in this paper.
Conclusions
In conclusion, this long-term cohort study of representa-
tive Japanese samples indicated that CVD mortality in
smokers without metabolic syndrome or without obesity
was substantially high and a large proportion of excess
deaths were observed in these groups. These findings
suggest that intervention targeting on smokers, irrespec-
tive of the presence of metabolic syndrome (or obesity), is
still important for the prevention of CVD death in rela-
tively lean Japanese population with high smoking rate.
This could apply to other Asian populations with high
smoking rate but with lower prevalence of obesity com-
pared with Western populations.Takashima et al. BMC Public Health 2010, 10:306
http://www.biomedcentral.com/1471-2458/10/306
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